Has Craig Surman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $110,816 in general payments to Craig Surman, MD across 85 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Craig Surman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Craig Surman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Craig Surman, MD

Psychiatry · Cambridge, MANPI 1912969874

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $75,881 of the $110,816 with a category attached, or 68.5%. 7 manufacturers reported payments, led by Adlon Therapeutics L.p. at 55.6% of the total. Reporting peaked in 2019 at $42,882 and has fallen 68.0% since, to $13,706 in 2023. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$110,816in general payments, 2019–2025

Across 85 payments — averaging $1303.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Adlon Therapeutics L.p.$62K
Supernus Pharmaceuticals, Inc.$25K
Teva Pharmaceuticals USA, Inc.$8K
Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
Eisai Inc.$5K
Shire North American Group Inc$4K
plus $13 from 1 others

$632,720in research payments, 2019–2025

Across 10 payments — averaging $63,272 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Jazz Pharmaceuticals Inc.$450K
Takeda Pharmaceuticals U.S.A., Inc.$101K
Shire North American Group Inc$67K
Purdue Pharma L.p.$15K

What the payments were for

Consulting fees$75,88168%
Speaking & faculty fees$22,78821%
Travel & lodging$6,5486%
Food & beverage$2,5782%
Education$3,0223%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Adlon Therapeutics L.p.	20	$61,627
Supernus Pharmaceuticals, Inc.	25	$25,274
Teva Pharmaceuticals USA, Inc.	9	$7,781
Otsuka Pharmaceutical Development & Commercialization, Inc.	8	$6,779
Eisai Inc.	15	$4,908
Shire North American Group Inc	7	$4,433
Purdue Pharma L.p.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ADHANSIA XR$61,454
QELBREE$12,281
AUSTEDO$7,699
Dayvigo$4,576
MYDAYIS$4,000

How this compares

$110,816 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$5,921

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Methylphenidate ErMethylphenidate Hcl	54	$6,628
Adderall XrDextroamphetamine/Amphetamine	19	$5,855
StratteraAtomoxetine Hcl	12	$5,311
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	27	$3,472
Methylphenidate Hcl	31	$676
Clonazepam	16	$35
Lorazepam	12	$35

Paid to pharmacies, not to this prescriber.

Other psychiatry in Cambridge

Jennifer BrownCambridge$37K
Theresa CerulliNorth Andover$724K
Andrew AldridgeMedford$407K
Amjad BahnassiWorcester$352K
Ximena Sanchez-SamperBoston$258K
Robert AlexanderBelmont$170K
George PapakostasBoston$170K
Xiangyang LiMilford$166K
Ernesto ZilberbergNorth Andover$141K
Maurizio FavaBoston$120K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →